share_log

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Wedbush維持對Kiniksa Pharmaceuticals的跑贏大盤評級,並將其目標股價上調至34美元。
Benzinga ·  2024/07/23 12:55  · 評級/大行評級

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $30 to $34.

Wedbush分析師David Nierengarten堅持認爲Kiniksa Pharmaceuticals(納斯達克股票代碼:KNSA)表現優異,將價格目標從30美元升至34美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論